Sue Pearson

Home Insights BioTrinity 2026 Showcases Delivery Technologies and Promising Therapeutic Candidates Credit: Alexey_ds/Getty Images European biotechs presented a range of interesting technologies and novel therapeutic biotechs at the recent BioTrinity conference, organized by BioUK, formerly OBN. The meeting highlighted a spectrum of cell and protein-based therapies, as well as novel delivery methods, with eye-catching investments and partnering opportunities.

1 INTRODUCTION Among Australian-born infants, an estimated 36% are exclusively breastfed to 6 months of age, and as few as 2.9% of mothers continue to breastfeed (any) to 12 months (Australian Institute of Health and Welfare, 2023).

Home Topics Cancer Streamlining CAR/TCR T-Cell Therapy Manufacturing Credit: Keith Chambers / Science Photo Library / Getty Images Credit: Keith Chambers / Science Photo Library / Getty Images Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to patients whose cancers have become refractory to conventional therapeutic options.